한국형 양극성 장애 약물치료 알고리듬 2022: 혼재성 양상
Korean Medication Algorithm Project for Bipolar Disorder 2022: Mixed Features
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives Treatment guidelines or an algorithm can help clinicians implement better practices and clinical decisions. Therefore, the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) was revised again through a consensus of expert opinion. The diagnosis and treatment of mixed features are not simple, and there are many things to discuss. We describe the preferences and recommendations from KMAP-BP 2022 for the treatment of mood episodes with mixed features. Methods We revised the KMAP-BP 2018 questionnaire and conducted the survey with expert clinicians. Out of ninety-three members of the review committee, eighty-seven completed the survey. We analyzed the answers, discussed the data, and held a clinician hearing. Results In first-step strategies for mixed features with more manic symptoms, a combination of a mood stabilizer and an atypical antipsychotic is the treatment of choice. Mood stabilizer monotherapy and atypical antipsychotic monotherapy are preferred strategies. For mixed features with more depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, a combination of atypical antipsychotic and lamotrigine (LMT), atypical antipsychotic monotherapy, a combination of mood stabilizer and LMT, and mood stabilizer monotherapy are preferred. For mixed features with similar manic symptoms and depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, atypical antipsychotic monotherapy, and mood stabilizer monotherapy are preferred. Conclusion For mixed features, a combination of mood stabilizer and atypical antipsychotic is generally preferred, and LMT is preferred for depressive symptoms. Compared with KMAP-BP 2018, more diverse strategies and drugs are being attempted for the treatment of mixed features.
Abstract
Objectives Treatment guidelines or an algorithm can help clinicians implement better practices and clinical decisions. Therefore, the Korean Medication Algorithm Project for Bipolar Disorder 2022 (KMAP-BP 2022) was revised again through a consensus of expert opinion. The diagnosis and treatment of mixed features are not simple, and there are many things to discuss. We describe the preferences and recommendations from KMAP-BP 2022 for the treatment of mood episodes with mixed features. Methods We revised the KMAP-BP 2018 questionnaire and conducted the survey with expert clinicians. Out of ninety-three members of the review committee, eighty-seven completed the survey. We analyzed the answers, discussed the data, and held a clinician hearing. Results In first-step strategies for mixed features with more manic symptoms, a combination of a mood stabilizer and an atypical antipsychotic is the treatment of choice. Mood stabilizer monotherapy and atypical antipsychotic monotherapy are preferred strategies. For mixed features with more depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, a combination of atypical antipsychotic and lamotrigine (LMT), atypical antipsychotic monotherapy, a combination of mood stabilizer and LMT, and mood stabilizer monotherapy are preferred. For mixed features with similar manic symptoms and depressive symptoms, a combination of mood stabilizer and atypical antipsychotic, atypical antipsychotic monotherapy, and mood stabilizer monotherapy are preferred. Conclusion For mixed features, a combination of mood stabilizer and atypical antipsychotic is generally preferred, and LMT is preferred for depressive symptoms. Compared with KMAP-BP 2018, more diverse strategies and drugs are being attempted for the treatment of mixed features.
참고문헌 (17)
- American Psychiatric Association, "Diagnostic and statistical manual of mental disorders" (2013), American Psychiatric Association
- Judd LL, "Prevalence and clinical significance of subsyndromal manic symptoms, including irritability and psychomotor agitation, during bipolar major depressive episodes", J Affect Disord, 138, pp.440~448 (2012)
- Kim W, "More inclusive bipolar mixed depression definitions by requiring fewer non-overlapping mood elevation symptoms", Acta Psychiatr Scand, 134, pp.189~198 (2016)
- Kim H, "More inclusive bipolar mixed depression definition by permitting overlapping and non-overlapping mood elevation symptoms", Acta Psychiatr Scand, 134, pp.199~206 (2016)
- 박원명, "양극성 장애의 한국형 약물치료 알고리듬", 대한정신약물학회지, 13(3), pp.205~221 (2002), 대한정신약물학회
- 김찬형, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅰ)：전반적 평가", 대한정신약물학회지, 16(3), pp.225~233 (2005), 대한정신약물학회
- 신영철, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅱ)：약물의 선택", 대한정신약물학회지, 16(4), pp.285~291 (2005), 대한정신약물학회
- 전덕인, "한국형 양극성 장애 약물치료 알고리듬의 적용 가능성(Ⅲ)：치료반응과 내약성", 대한정신약물학회지, 16(4), pp.292~300 (2005), 대한정신약물학회
- Jon DI, "Revised Korean medication algorithm for bipolar disorder", World J Biol Psychiatry, 10(4 Pt 3), pp.846~855 (2009)
- Shin YC, "Korean medication algorithm for bipolar disorder : second revision", Asia Pac Psychiatry, 5, pp.301~308 (2013)
- Woo YS, "Korean medication algorithm project for bipolar disorder : third revision", Neuropsychiatr Dis Treat, 11, pp.493~506 (2015)
- Sachs GS, "The expert consensus guideline series: medication treatment of bipolar disorder 2000", Postgrad Med, pp.1~104 (2000)[DOI]
- Goodwin GM, "Evidence-based guidelines for treating bipolar disorder : revised third edition recommendations from the British Association for Psychopharmacology", J Psychopharmacol, 30, pp.495~553 (2016)
- (2014)[URL]
- Yatham LN, "Canadian Network for Mood and Anxiety Treatments (CANMAT)and International Society for Bipolar Disorders (ISBD) 2018guidelines for the management of patients with bipolar disorder", Bipolar Disord, 20, pp.97~170 (2018)
- Fountoulakis KN, "The International College of Neuro-Psychopharmacology (CINP) treatment guidelines for bipolar disorder in adults (CINP-BD-2017), part 3:the clinical guidelines", Int J Neuropsychopharmacol, 20, pp.180~195 (2017)
- Grunze H, "The World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for the biological treatment of bipolar disorders : acute and long-term treatment of mixed states in bipolar disorder", World J Biol Psychiatry, 19, pp.2~58 (2018)